ノバルティス

 NVSのチャート


 NVSの企業情報

symbol NVS
会社名 Novartis AG Basel (ノバルティス)
分野(sector)   
産業(industry)   
業種 医薬品   医療関連(Health Care)
概要 ノバルティス(Novartis AG)はヘルスケア・ソリューションを提供する持株会社である。同社は医薬品を主としてヘルスケア製品の研究・開発・製造・販売に従事する。同社の事業は医薬品、サンドズ、アルコンとコーポレート活動を含む。医薬品事業は患者と医療提供者のための健康成果を開発するために特許を取得した処方薬を研究、開発、製造、販売、販売する。サンドズ事業は処方薬、有効・執行可能な第三者特許で保護されない医薬品有効成分を開発、製造、販売する。アルコン事業はアイケア製品を研究、開発、製造、販売する。アルコン事業は眼科医療機器と視力ケア製品の提供を行う。同社の製品には、医薬品、腫瘍薬、ジェネリック医薬品、バイオシミラー薬、眼科機器を有する。  ノバルティスはスイスの大手医薬品・バイオテクノロジ―企業。心血管代謝、免疫抑制、皮膚病、網膜、呼吸器など広範な領域で処方薬の研究、開発、生産、販売を展開。また、ジェネリック医薬品の開発、生産、販売に加え、眼科用医療機器、眼科手術器具・消耗品、コンタクトレンズや洗浄液などのアイケア製品も扱う。同社の製品は約180カ国で販売される。  
本社所在地 Lichtstrasse 35 Basel CH-4056 CHE
代表者氏名 Vasant Narasimhan
代表者役職名 Chief Executive Officer Member of the Executive Committee
電話番号 +41 61-324-1111
設立年月日 1895年7月
市場名 NYSE(ニューヨーク証券取引所)
ipoyear
従業員数 125161人
url www.novartis.com
nasdaq_url
adr_tso
EBITDA (百万ドル) 17697.00000
終値(lastsale)
時価総額(marketcap)
時価総額 (百万ドル) 240518.10000
売上高 (百万ドル) 53166.00000
企業価値(EV) (百万ドル) 256702.10000
当期純利益 (百万ドル) 12611.00000
決算概要 BRIEF: For the fiscal year ended 31 December 2018 Novartis AG (ADR) revenues increased 6% to $53.17B. Net income before extraordinary items increased 65% to $12.61B. Revenues reflect Innovative Medicines segment increase of 8% to $34.89B Alcon segment increase of 6% to $7.15B Other Foreign- segment increase of 6% to $22.17B United States segment increase of 4% to $17.56B Germany segment increase of 13% to $4.18B.

 NVSのテクニカル分析


 NVSのニュース

   Novartis Q2 2021 Earnings Preview  2021/07/20 15:46:19 Seeking Alpha
   Novartis Pharma AG: Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity  2021/07/20 11:17:00 FinanzNachrichten
Novartis and the Novartis US Foundation to join forces with Thurgood Marshall College Fund, Morehouse School of Medicine, 26 other Historically Black Colleges, Universities and Medical Schools and
   Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable solutions for health equity  2021/07/20 11:05:00 Intrado Digital Media
Basel, July 20, 2021 Novartis and the Novartis US Foundation today announced a planned 10-year collaboration with Coursera, the National Medical Association, Thurgood Marshall College Fund, Morehouse School of Medicine and 26 additional Historically Black Colleges, Universities and Medical Schools (HBCUs) to co-create programs that address the root causes of systemic disparities in health outcomes and create greater diversity, equity and inclusion across the research and development ecosystem.
   Diabetic Nephropathy Market Report 2021-2028 | Size, Share, Growth, Trends, Competitive Landscape, Revenue, Analysis, Forecast Report  2021/07/20 09:56:00 Intrado Digital Media
Top Players Covered in the Diabetic Nephropathy Market Research Report are Merck & Co., Inc., Abbott, Pfizer Inc., Siemens, Novartis AG, GENERAL ELECTRIC COMPANY, Bayer AG, Mitsubishi Tanabe Pharma Corporation, Renata Limited, and others. and other key market players Top Players Covered in the Diabetic Nephropathy Market Research Report are Merck & Co., Inc., Abbott, Pfizer Inc., Siemens, Novartis AG, GENERAL ELECTRIC COMPANY, Bayer AG, Mitsubishi Tanabe Pharma Corporation, Renata Limited, and others. and other key market players
   Insights on the Losartan Global Market to 2026 - Featuring Pfizer, Teva Pharmaceutical Industries and Sanofi Among Others  2021/07/20 07:53:00 Intrado Digital Media
Dublin, July 20, 2021 (GLOBE NEWSWIRE) -- The "Global Losartan Market, By Source (Contract Manufacturing Organizations, In-House), By Form (Tablet, Powder), By Strength (25mg, 50mg, 100mg, Others), By Distribution Channel (Offline, Online), By Application, By End-User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com''s offering. The Global Losartan Market was valued at $4.73 billion in 2020 and is expected to grow at a formidable rate of 7.81% during the forecast period. The Global Losartan Market is driven by the growing prevalence of hypertension, stroke and diabetic nephropathy across the world. Losartan is a medication that is used to treat high blood pressure. Furthermore, losartan is widely used in slowing down long-term kidney damage due to type II diabetes which is further expected to propel the market growth through 2026. The sudden outbreak and spread of the COVID-19 pandemic has resulted in the loss of jobs for many people due to which the level of anxiety and hypertension has increased among the people.
   FinTech Market 2021- PolicyGenius, EquityZen, Quovo, Novus  2021/06/30 12:00:00 Jumbo News
The Global FinTech Market Perspective, Comprehensive Analysis along with Major Segments and Forecast, 2020-2025. The FinTech Market report is a valuable source of insightful data for business strategists. It offers the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The report explores the current outlook in global and key regions []
   Novus Innovation Corridor Achieves National Sustainability Recognition  2021/06/29 19:29:40 Gteater Phoenix In Business
In a first for Arizona, the Novus Innovation Corridor earned LEED-ND Gold certification last month from the U.S. Green Building Council. Novus, the 355-acre mixed-use, public-private partnership between Arizona State University and Catellus Development Corporation adjacent to the ASU Tempe campus, is the first LEED-ND community certified at any level in Arizona. This is a [More] The post Novus Innovation Corridor Achieves National Sustainability Recognition appeared first on Greater Phoenix In Business Magazine .
   iConnections Deepens Analytics and Data Offerings with Novus Partnership  2021/06/24 13:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)--iConnections, the industry-leading platform and community that seamlessly connects investment managers and allocators, today announced that it is partnering with Novus, the leading portfolio intelligence platform, allowing managers and allocators to access Novus data and analytics through the iConnections platform. iConnections members will be able to access Novus research, including manager league tables, the Novus 4C indices (tracking important hedge fund holdings
   Swedish PM Lofven remains publics top choice despite losing no-confidence vote RT World News  2021/06/24 10:39:05 State Of Press
Swedish Prime Minister Stefan Lofven is still the countrys most popular leader, according to a poll released on Thursday, amid an ongoing political crisis following a no-confidence vote in parliament earlier this week. A Novus poll conducted in the wake of the no-confidence vote found that 38% of Swedish voters still have faith in Lofven,
   Swedish PM Lofven still voters favourite leader despite crisis  2021/06/24 08:07:43 Metro US
STOCKHOLM (Reuters) Social Democrat Prime Minister Stefan Lofven is Swedish voters most trusted leader, a poll showed on Thursday, despite a crisis that saw parliament pass a vote of no-confidence in him at the start of the week. The Novus poll showed 38% of Swedes have confidence in Lofven, ahead of his most likely Read More
   WATCH: Covid-19 knocks Novus into the red  2021/06/14 05:26:15 BusinessLIVE
Novus CEO Neil Birch talks to Business Day TV about the companys annual results
   Novus gives and receives at this years PSA awards  2021/06/11 15:11:47 WATT Global Media
Novus gives and receives at this years PSA awards.
   Quantamental approach gains ground  2021/06/10 14:04:42 Hedgeweek
Quantamental approach gains ground Submitted 10/06/2021 - 3:04pm By A Paris The volatility experienced since the start of the Covid-19 pandemic in March 2020 has largely been a positive development for alpha-hunting hedge fund managers who were able to take advantage of the arbitrage opportunities available. However, various market forces saw those at extreme ends of the investment approaches come under pressure causing the convergence of quantitative and fundamental philosophies to rise in appeal. The spectrum of investment approaches is very diverse with fundamental investors using traditional metrics like balance sheet evaluations at one end, and strictly quant managers whose investment decisions are driven by statistical models. The investment spectrum has shifted in an incredible way. People who were purely fundamental investors are being pushed to use new data sources and the quant side is starting to understand the value of the human element, says Michael Perlow, founder of Epsilon Asset Management.
   WATCH: Stock picks foreign currencies and Novus  2021/06/10 07:00:50 BusinessLIVE
Wayne McCurrie from FNB Wealth & Investments and David Shapiro from Sasfin Securities talk to Business Day TV
   Novus celebrates 30th anniversary, gears up for a long sustainable future  2021/06/10 04:09:00 The Philippine Business & News
Novus reaches another milestone as it celebrated 30 years last June 6 and takes pride in supporting animal protein producers globally who are working to feed the world. In 1991, Novus International, Inc. was founded with a mission to make a clear difference in sustainability meeting the growing global need for nutrition and health. The [] The post Novus celebrates 30th anniversary, gears up for a long sustainable future appeared first on The Philippine Business and News .

 関連キーワード  (医薬品 米国株 ノバルティス NVS )

 twitter  (公式ツイッターやCEOツイッターなど)

NVS動画